根据最新合作协议，丹麦制药巨头诺和诺德(Novo Nordisk)与美国远程医疗平台Hims & Hers Health Inc.将共同为美国消费者开启新型减重疗法通道。消费者可通过自费方式获得诺和诺德旗下三款明星产品：Ozempic注射剂、Wegovy口服片剂及Wegovy注射剂。
此次合作标志着诺和诺德在拓展美国零售市场战略迈出关键一步。通过Hims & Hers的数字化医疗平台，患者无需经过传统保险理赔流程，即可直接以自付费用形式获取这些经临床验证的代谢类治疗药物。
值得注意的是，Wegovy口服片剂作为诺和诺德最新研发成果，其便利性有望颠覆传统注射类减重药物的使用体验。而Ozempic注射剂与Wegovy注射剂作为经过市场验证的成熟产品，将共同构成完整的体重管理解决方案。
这一创新合作模式不仅降低了患者获取处方药的门槛，更展现了制药企业与数字健康平台深度融合的行业趋势。对于正在寻找替代传统分销渠道的诺和诺德而言，与Hims & Hers的合作或将开创代谢疾病管理的新范式。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.